Alnylam Pharmaceuticals Inc [ALNY] stock is trading at $273.55, up 5.46%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The ALNY shares have gain 7.34% over the last week, with a monthly amount glided 4.34%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Alnylam Pharmaceuticals Inc [NASDAQ: ALNY] stock has seen the most recent analyst activity on March 31, 2025, when Redburn Atlantic initiated its Buy rating and assigned the stock a price target of $353. Previously, JP Morgan upgraded its rating to Overweight on March 24, 2025, and elevated its price target to $328. On November 12, 2024, downgrade downgraded it’s rating to Underperform. Scotiabank started tracking the stock assigning a Sector Outperform rating. Goldman upgraded its rating to a Buy and raised its price target to $370 on August 16, 2024. Goldman downgraded its rating to Neutral for this stock on February 16, 2024, but kept the price target unchanged to $173. In a note dated February 15, 2024, Wolfe Research initiated an Peer Perform rating.
Alnylam Pharmaceuticals Inc [ALNY] stock has fluctuated between $144.73 and $304.39 over the past year. Currently, Wall Street analysts expect the stock to reach $324 within the next 12 months. Alnylam Pharmaceuticals Inc [NASDAQ: ALNY] shares were valued at $273.55 at the most recent close of the market. An investor can expect a potential return of 18.44% based on the average ALNY price forecast.
Analyzing the ALNY fundamentals
Alnylam Pharmaceuticals Inc [NASDAQ:ALNY] reported sales of 2.35B for the trailing twelve months, which represents a growth of 20.20%. Gross Profit Margin for this corporation currently stands at 0.86% with Operating Profit Margin at -0.05%, Pretax Profit Margin comes in at -0.15%, and Net Profit Margin reading is -0.11%. To continue investigating profitability, this company’s Return on Assets is posted at -0.06, Equity is -5.09 and Total Capital is -0.04. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of11.28.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 262.53 points at the first support level, and at 251.51 for the second support level. However, for the 1st resistance point, the stock is sitting at 279.27, and for the 2nd resistance point, it is at 284.99.
Ratios To Look Out For
For context, Alnylam Pharmaceuticals Inc’s Current Ratio is 3.04. In addition, the Quick Ratio stands at 2.98 and the Cash Ratio stands at 0.95. Considering the valuation of this stock, the price to sales ratio is 15.19, the price to book ratio is 308.80.
Transactions by insiders
Recent insider trading involved Garg Pushkal, CMO & EVP Dev & Med Affairs, that happened on Mar 24 ’25 when 5445.0 shares were sold. CMO & EVP Dev & Med Affairs, Garg Pushkal completed a deal on Mar 21 ’25 to sell 4321.0 shares. Meanwhile, Director PYOTT DAVID E I sold 7440.0 shares on Mar 24 ’25.
